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Abstract
Reduced expression of proapoptotic and terminal differentiation genes in conjunction with increased
levels of the proinflammatory and angiogenesis-inducing enzymes, cyclooxygenase 2 (COX-2) and
inducible nitric oxide synthase (iNOS), correlate with malignant transformation of oral intraepithelial
neoplasia (IEN). Accordingly, this study investigated the effects of a 10% (w/w) freeze-dried black
raspberry gel on oral IEN histopathology, gene expression profiles, intraepithelial COX-2 and iNOS
proteins, and microvascular densities. Our laboratories have shown that freeze-dried black
raspberries possess antioxidant properties and also induce keratinocyte apoptosis and terminal
differentiation. Oral IEN tissues were hemisected to provide samples for pretreatment diagnoses and
establish baseline biochemical and molecular variables. Treatment of the remaining lesional tissue
(0.5 g gel applied four times daily for 6 weeks) began 1 week after the initial biopsy. RNA was
isolated from snap-frozen IEN lesions for microarray analyses, followed by quantitative reverse
transcription-PCR validation. Additional epithelial gene-specific quantitative reverse transcription-
PCR analyses facilitated the assessment of target tissue treatment effects. Surface epithelial COX-2
and iNOS protein levels and microvascular densities were determined by image analysis quantified
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immunohistochemistry. Topical berry gel application uniformly suppressed genes associated with
RNA processing, growth factor recycling, and inhibition of apoptosis. Although the majority of
participants showed posttreatment decreases in epithelial iNOS and COX-2 proteins, only COX-2
reductions were statistically significant. These data show that berry gel application modulated oral
IEN gene expression profiles, ultimately reducing epithelial COX-2 protein. In a patient subset, berry
gel application also reduced vascular densities in the superficial connective tissues and induced genes
associated with keratinocyte terminal differentiation.
Introduction
Oral squamous cell carcinoma (SCC) is a worldwide health problem that is associated with
significant morbidity, mortality, and an economic cost that rivals or exceeds other solid tumors
(1–3). Recognized risk factors for the development of oral SCC include tobacco and alcohol
use, poor oral hygiene, and potentially high-risk human papilloma virus subtypes (4,5). Other
data also imply a role for sustained inflammation in oral SCC pathogenesis (6,7). Increased
expression of two inflammation-induced proinflammatory enzymes, cyclooxygenase 2
(COX-2) and inducible nitric oxide synthase (iNOS), is associated with malignant
transformation of precancerous oral lesions (8–10). Notably, high levels of COX-2– and iNOS-
generated reactive oxygen and nitrogen species can promote tumorigenesis by a variety of
mechanisms (6,7). Oxidative and nitrosative stresses can induce nuclear and mitochondrial
DNA mutations and inactivation of key cytoprotective enzymes such as manganese superoxide
dismutase (11). In addition, increased COX-2 activity is associated with the suppression of
apoptosis, oxygenase-mediated bioactivation of carcinogens, and reductase-induced
conversion of compounds to potential mutagens (12). iNOS activation induces angiogenesis
via nitric oxide’s ability to serve as a signaling molecule for vascular endothelial growth factors
(VEGF; ref. 13), and up-regulates basic fibroblast growth factor (14). Finally, as nitric oxide
directly activates both of the COX isoforms (15), there is a positive correlation between cellular
nitric oxide levels and COX function.
Oral intraepithelial neoplasia (IEN), histopathologically described as grades of epithelial
dysplasia, is the recognized precursor to oral SCC. Oral IEN lesions present as white, red, or
erythroleukoplakic patches (16). Although up to 36% of oral IEN lesions undergo malignant
transformation, we cannot predict which lesions will progress (17). Although complete surgical
excision remains the standard of care for advanced lesions, i.e., moderate dysplasia or higher,
recurrences of lesional tissue or development of new premalignant lesions are not uncommon
(18). Repeated surgeries increase costs and morbidity and negatively affect the ability to
conduct clinical exams due to the accumulation of scar tissue.
Chemoprevention is a potential primary or adjunctive oral IEN treatment strategy. Black
raspberries are one food that has shown significant chemopreventive efficacy (19–29).
Furthermore, the freeze-drying process concentrates black raspberries’ bioactive constituents
~10-fold on a weight basis relative to the natural fruit (27). Freeze-dried black raspberries
(FBR) contain appreciable quantities of many putative chemopreventive compounds including
vitamins A, C, and E, folic acid, calcium, selenium, α and β carotene, ellagic acid, ferulic acid,
coumaric acid, and quercitin in addition to multiple anthocyanins and phytosterols (20,24).
Our data show the ability of FBR to suppress redox-mediated intracellular signaling (21),
inhibit survival pathways in transformed cells (19), reduce production of proangiogenic
cytokines (22,25), and stimulate apoptotic and terminal differentiation pathways (22). In
vivo, dietary administered FBR suppressed carcinogenesis in both hamster cheek pouch (23)
and rat esophageal cancer models (24–26), inhibited the expression of COX-2 and iNOS
(26), and suppressed tumor-associated angiogenesis (25). In addition, phase I human clinical
trials have shown that orally administered FBR were well-tolerated (27,28) and also showed
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the potential for FBR metabolism following oral administration by the detection of berry
metabolites in the urine (29). Recently, our laboratories formulated a 10% FBR (w/w)
bioadhesive berry gel for application to the human oral mucosa (30). Results from this clinical
trial show that berry gel topical application significantly reduces loss of heterozygosity (LOH)
indices at chromosomal loci associated with tumor suppressor genes in human oral IEN lesions
without induction of any deleterious side effects (31).
We hypothesized that due to the anti-inflammatory and antioxidant properties of FBRs and
their ability to suppress redox-mediated cell signaling, FBR gel application would be clinically
active in oral IEN lesions. Accordingly, this study evaluated the effects of topical application
of a 10% (w/w) FBR bioadhesive gel on oral IEN variables that included: histopathologic
diagnosis, gene expression profiles, lesional epithelial COX-2 and iNOS levels, and
microvascular density (MVD) of the superficial connective tissue. Our data show that berry
gel application uniformly suppressed genes associated with RNA processing, growth factor
recycling, and inhibition of apoptosis, and significantly reduced epithelial COX-2 levels.
Furthermore, in a subset of patients, gel application also induced genes associated with
apoptosis and keratinocyte terminal differentiation and reduced MVD.
Materials and Methods
Berry gel manufacturing
The bioadhesive gels used in this clinical trial were prepared using current good manufacturing
practices at the cGMP facility within the Center for Pharmaceutical Science and Technology
at the University of Kentucky, Lexington, KY. A description of the quality control measures
and details of the gel composition and method of manufacture have been described previously
(30). Briefly, the gel composition used for the clinical trial consisted of (in %, w/w): Noveon
AA1 (NF; Noveon, Inc.) 1.35%, Carbopol 971P (NF; BF Goodrich Specialty Chemicals)
1.575%, glycerin (USP) 1.0%, edentate disodium (USP) 0.1%, 2-phenoxyethanol (BP) 1.0%,
benzyl alcohol (USP) 1.0%, FBR 10%, and purified water as needed to obtain 100% (30).
Based on our previous stability and mucosal penetration data (30), slight modifications of the
prototype gel were made for the clinical trial gel. The FBR concentration was increased to 10%
(w/w) and the pH of the gel was fixed at pH 3.5 to stabilize the more biologically active
flavylium cation of the anthocyanin molecules.
Human clinical trials
Thirty-two adults (age range, 18–76 years) consented to participate in our clinical trial, which
received approval from The Ohio State University Institutional Review Board (protocol
2003C0050). Criteria for inclusion as IEN participants were microscopically confirmed
premalignant oral epithelial changes (noninvasive disease) and no use of tobacco products for
6 weeks prior to, or for the duration of, the clinical trial. Exclusion criteria included use of
tobacco products within 6 weeks prior to or during the clinical trial, or a microscopic diagnosis
of invasive oral SCC. Twenty participants had oral lesions that were clinically consistent with,
and microscopically confirmed, as premalignant oral lesions (histopathologic diagnoses ranged
from epithelial atypia to severe dysplasia, see Table 1A). The site, size, and consistency of
premalignant lesions were recorded and clinical photographs obtained. Patient no. 4 (normal
histology) and no. 16 (biopsy-confirmed invasive oral SCC) did not meet the study criteria and
were therefore excluded from participation.
The remaining 10 individuals (five men and five women, aged between 24 and 34 years)
exhibited clinically normal oral mucosa, and were included as trial participants (a) to allow
additional observations for treatment-associated side effects, and (b) to evaluate the clinical
and histopathologic effects of berry gel application on normal oral mucosa. The normal
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participants’ treatment protocol was identical to the IEN patients except that only a
posttreatment biopsy was taken to reduce morbidity. Seven of these 10 normal participants had
never used tobacco products or alcohol. The remaining three normal participants reported
negligible (one participant) and modest alcohol (two participants) consumption with no tobacco
use.
At the initial treatment appointment, half of the IEN tissue was excised, a portion placed in
10% neutral buffered formalin for histopathology and immunohistochemical studies, and a
portion immediately frozen for microarray and reverse transcription-PCR (RT-PCR) analyses.
This protocol ensured that pretreatment indices for each variable to be evaluated were obtained,
thereby allowing each IEN participant to serve as their own internal control. Treatment entailed
multiple dosing throughout the day, 0.5 g applied four times daily for 6 weeks for a total 84 g
applied over the study duration. As human oral epithelium regenerates approximately every
28 days, a 6-week duration ensured the presence of FBR for at least one complete cycle of
epithelial regeneration. Gel effects on LOH indices at loci associated with tumor suppressor
genes in this cohort are reported separately (31).
Because the ventral-lateral tongue is a high incidence site for oral IEN and SCCs (4,6), this
location was selected as the gel application site for the normal participants. All participants
were monitored during the trial to observe for any adverse side effects, and in persons with
premalignant lesions, any clinical progression in lesional tissue. All participants returned their
used gel tubes at each weekly follow-up visit. Toxicity was assessed using National Cancer
Institute common toxicity criteria version 3.0. Any toxicity equivalent to grade 2 or higher was
considered dose-limiting.
Clinical photographs were taken, and biopsies obtained from the treated ventral-lateral tongue
of the normal participants upon study conclusion. In the persons with premalignant lesions,
excisional biopsies, which included the residual treated lesional tissue and initial biopsy site,
were conducted. Tissue samples were handled as previously described.
Light microscopic diagnoses of all tissues were based on a seven-grade scale (normal,
hyperkeratosis, atypia, mild dysplasia, moderate dysplasia, severe dysplasia, carcinoma in
situ, invasive SCC). In this study, the diagnosis “hyperkeratosis” alone conveyed a benign,
reactive change without evidence of premalignant potential. In contrast, “atypia” signified
architectural and cytologic alterations that in the clinical setting of an adherent demarcated
white plaque represents early premalignant change. Two board-certified oral and maxillofacial
pathologists reached agreement before a final histopathologic diagnosis was rendered.
RNA isolation and microarray analyses
Total RNA was isolated from snap-frozen patient biopsies using Absolutely RNA Miniprep
Kit (Stratagene). The RNA concentrations were measured using Nanodrop ND-1000
(Nanodrop). The integrity of the total RNA was evaluated using capillary electrophoresis
(Bioanalyzer 2100, Agilent Technologies) and quantified using a Nanodrop 1000 (Nanodrop).
Following confirmation of RNA quality, an Ovation Biotin RNA Amplification and Labeling
System (NuGen Technologies, Inc.) was used to prepare amplified, biotin-labeled cDNA from
total RNA following the instructions of the manufacturer. Briefly, first-strand cDNA was
synthesized from 25 ng of total RNA using a unique first-strand DNA/RNA chimeric primer
and reverse transcriptase. Following double-strand cDNA generation, amplification of cDNA
was achieved by using an isothermal DNA amplification process that involves repeated SPIA
DNA/RNA primer binding, DNA duplication, strand displacement, and RNA cleavage. The
amplified SPIA cDNA was purified and subjected to a two-step fragmentation and labeling
process. The fragmented/biotinylated cDNA content was measured in a ND-1000
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spectrophotometer and the quality was analyzed on an RNA 6000 Nano LabChip (Agilent)
using an Agilent Bioanalyzer 2100.
For each array, 2.2 μg of cDNA was hybridized onto Human Genome 133A GeneChips
(Affymetrix, Inc.), containing probe sets that measure 22,000 transcripts from Human RNA.
Sequences used in the design of the array were selected from GenBank, dbEST, and RefSeq.
The sequence clusters were created from the UniGene database (Build 133, April 20, 2001)
and were then refined by analysis and comparison with a number of other publicly available
databases including the Washington University EST trace repository and the University of
California, Santa Cruz Golden-Path human genome database (April 2001 release).
Hybridization was conducted for 16 h at 45°C followed by washing and staining of microarrays
in a Fluidics Station 450 (Affymetrix). GeneChips were scanned in a GeneChip Scanner 3000
(Affymetrix) and CEL files generated from DAT files using GeneChip Operating Software
(Affymetrix). The probe set signals, which were generated using the RMA algorithm in
ArrayAssist 3.4 (Stratagene), were used to determine differential gene expression by pair-wise
comparisons. The genes that were altered by 1.5-fold either way were sorted and used for
further interpretation of the microarray data. Microarray data were validated by conduction of
quantitative RT-PCR analyses on three consistently down-regulated genes (SFRS7, SFRS11,
and LGALS8) and five up-regulated genes (KRT2B, DSC1, UGT2B, SPPR3, and UBD), using
matched pretreatment and posttreatment RNA from four donors for each gene evaluated. In
order to establish which pathways were affected by gel treatment, microarray analyses were
conducted midway through the trial on 13 matched pretreated and posttreated IEN samples.
Quantitative RT-PCR analyses
Total RNA (100 ng) was reverse-transcribed using High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems). All gene-specific TaqMan MGB primer and probes
(FAM dye-labeled) and human β-glucuronidase (β-GUS) endogenous control (VIC dye-
labeled) were purchased from Applied Biosystems. Real-time PCR was performed using
Applied Biosystems 7500 real-time PCR system. One microliter of cDNA was used in a total
volume of 20 μL real-time PCR reaction containing 10 μL of TaqMan Universal PCR Master
Mix, 1 μL of gene-specific TaqMan MGB primer and probe, and 1 μL of human β-GUS. The
PCR was run with an initial AmpErase enzyme activation step at 50°C for 2 min, followed by
a run at 95°C for 10 min and 40 cycles at 95°C for 15 s, and at 60°C for 1 min. The comparative
CT method was used to calculate RNA expression level. The amount of target, normalized to
a β-GUS endogenous control and relative to the normal patients, is given by , where
ΔΔCT = ΔCT (target) − ΔCT (mean value of normal patients), ΔCT is the CT target gene
subtracted from the CT of β-GUS, and CT is the threshold cycle.
Immunohistochemistry and image analysis for epithelial COX-2 and iNOS
COX-2 and iNOS protein staining was conducted on serially sectioned paraffin-embedded
pretreatment and posttreatment specimens from all of the IEN patients. Endogenous peroxidase
activity was blocked by pretreatment with 3% H2O2, followed by microwave processing to
facilitate antigen retrieval. Sections were then treated with 5% normal serum, 1% bovine serum
albumin, 0.05% Tween 20 for 1 h, and then incubated with either the primary antibody [goat
anti–COX-2 polyclonal antibody, 2 μg/mL dilution (Cayman Chemical), or anti-iNOS rabbit
polyclonal antibody, 1:500 dilution (Biomol International)] or PBS (negative control) at 4°C
overnight. Vectastain ABC reagent (Vector Laboratories) was then applied and sections
incubated for 30 min. Immunoreactions of methyl green counterstained sections were
visualized using the VIP substrate (Vector). Images were captured using a DS-Fi1 5-megapixel
color digital camera (Nikon). The percentages of positive staining areas were analyzed using
Image-Pro Plus 6.2 software (Media Cybernetics). The area of interest was defined as the entire
epithelium excluding the acellular keratin layer.
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Immunohistochemical staining for CD34 and determination of MVD
From the 20 IEN biopsy samples, 11 matched sets retained sufficient tissue for further studies.
These samples were stained and analyzed to determine MVD. Five-micron sections were
mounted on SuperFrost Plus slides (Fisher Scientific) and then successively deparaffinized,
rehydrated, treated with 3% hydrogen peroxide in methanol for 10 min to block endogenous
peroxidase, and microwaved in citrated buffer (pH 6.0) for antigen retrieval. Sections were
then blocked in 5% normal horse serum, 1% bovine serum albumin, 0.05% Tween 20 in PBS,
incubated with anti-CD34 mouse monoclonal antibody (1:20, BioGenex), washed, and then
incubated with biotinylated horse anti-mouse IgG (1:200) followed by horseradish peroxidase–
conjugated avidin complex (Vectastain ABC kit, Vector Laboratories). The sections were then
developed with 3,3′-diaminobenzidine (Vector Laboratories) and counterstained with
hematoxylin.
The CD34-stained tissue sections were captured at 200-fold image scale [microscopic field,
1,280 × 960 pixels (width × height), 300 dpi resolution] using a Nikon DS-Fi-1 5-megapixel
digital camera and Image-Pro Plus software. The images were imported into Adobe
PhotoDeluxe software, and displayed on a high-resolution 17-inch color monitor. The area of
interest was defined as the connective tissue located 90 μm underlying the most inferior
epithelial rete ridge. Microvessels were then manually counted on the computer screen. Any
single brown-stained cell (CD34 positive) or cluster of endothelial cells was counted as a single
vessel. MVD was calculated as the mean number of microvessels per area of interest in the
microscopic computerized field (×200 magnification).
Statistical analyses
The effects of berry gel application on surface epithelial COX-2 and iNOS proteins were
analyzed using a Wilcoxon sign rank test. Findings with P < 0.05 values were considered to
be significant.
Results
Berry gel use elicited no deleterious effects
Toxic responses such as hematologic disturbances would not be anticipated with the use of a
natural product. There were concerns, however, regarding potential complications such as a
contact mucositis, or due to the sugar content in berries, Candidal infections. None of the 30
trial participants developed any adverse effects. Furthermore, the treated tissue sites in the
normal tissue donors retained normal clinical and microscopic appearances (data not shown).
As determined by the minimal residual gel in the returned berry gel tubes (>95% dose used),
patient compliance was high.
Oral IEN lesion participant demographics and histopathologic diagnoses
Table 1A depicts the IEN patient demographics and histopathologic diagnoses. Follow-up
information on a subset of these patients (Table 1B) following the clinical trial is discussed
later. IEN patients were older than the normal tissue donors, and the majority had a previous
history of tobacco and alcohol use. Seventy percent of the patients had either multifocal lesions
and/or a history of recurrent disease at the selected treatment site, factors associated with a
higher-risk cohort which is more recalcitrant to treatment. Histopathologic improvement was
seen in seven patients’ lesions, disease progression (increase) in grade in four patients, and
nine patients’ lesions exhibited no change (stable disease) in microscopic appearance. Lesional
grade decreases were not restricted to lower grade lesions as the pretreatment diagnoses were
severe or moderate dysplasia in 20% (4 out of 20) of the seven lesions that showed histologic
improvement (Table 1A). The youngest IEN patient (no. 9), who had three previous diagnoses
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of epithelial dysplasia at the treatment site (these biopsies preceded her entrance into the clinical
trial), had complete clinical and microscopic lesional regression following treatment. This site
has retained a normal histology 15 months following trial cessation (Table 1B). The
posttreatment biopsy of patient no. 8 showed an increase of three grades, from mild dysplasia
(pretreatment) to focal carcinoma in situ (posttreatment). Patient no. 8’s lesional tissue was
remarkable for its extremely subtle clinical appearance, which introduced the prospect of
sampling error at the pretreatment biopsy.
Clinical measurements were not used as therapeutic indicators due to our study design (lesional
tissues hemisected to provide baseline variables) and the fact that the clinical appearances of
oral IEN lesions are dynamic and can vary from week to week, regardless of treatment (17).
Although pretreatment IEN lesions ranged from 0.3 × 0.3 to 2.5 × 1.5 cm (Table 1A),
pretreatment sizes had no apparent effects on therapeutic responsiveness.
Modulation of oral IEN gene expression profiles by berry gel application
Functional annotation groupings and their corresponding Benjamini scores were used to
identify genes consistently down-regulated following gel treatment. Twenty-seven genes,
which encompassed RNA processing, signal transduction, and inflammatory pathways showed
uniform down-regulation (mean decrease ≥ 1.5-fold) following berry gel application (Table
2). The majority (13) of the down-regulated genes involved RNA processing and included
transcriptional activation, RNA splicing, and nuclear export. Other down-regulated genes
included DUSP5, CTSL2, PIGL (signaling pathways) and LGALS8, RNASET2, and CFLAR,
which function in integrin-associated interactions, chromosomal rearrangements, and
inhibition of apoptosis, respectively. These latter three genes are frequently up-regulated in
cancers (32,33).8 The remaining down-regulated genes serve in protein trafficking, and
proinflammatory responses. The RT-PCR validation studies showed comparable fold changes
to those detected by microarray analyses (Table 2).
Up-regulation of apoptotic and terminal differentiation genes occurred in a subset of patients
Although consistent down-regulatory effects were identified, posttreatment increases in gene
expression showed greater variability. Microarray analyses revealed that a subset of patients’
IEN lesions responded to berry gel application with up-regulation of proapoptotic and terminal
differentiation pathways (Table 3). The gene panel selected for RT-PCR analyses therefore
included these microarray-identified genes in addition to genes that had either protumorigenic
functions, e.g., COX-2, iNOS, VEGF, or were associated with epithelial terminal
differentiation. As is apparent from the data shown in Table 3, there was considerable
interpatient heterogeneity with regard to which genes showed a modulation in expression and
the magnitude of the effect(s). Consistent with the findings of other investigators (34,35), data
from Table 3 reveals that genes which showed an appreciable increase by microarray analyses
showed an even greater expression increase when evaluated by RT-PCR.
Topical black raspberry gel reduces the levels of COX-2 and iNOS proteins in treated lesional
epithelium
COX-2 and iNOS proteins showed distinct and different intraepithelial distributions.
Furthermore, the relative intensities for both COX-2 and iNOS varied from patient to patient
and treatment status. COX-2 distribution showed an epithelial layer specificity, i.e., COX-2
was located in the spinous and granular layers, with negligible COX-2 immunoreactivity
observed in the basal cells (Fig. 1). In contrast, iNOS was more diffusely distributed throughout
8http://www.ncbi.nlm.nih.gov/sites/entrezgene
Mallery et al. Page 7













the surface epithelium and some tissues showed iNOS positivity within the basal layer cells
(Fig. 1).
Seventeen of the 20 matched pretreatment and posttreatment samples showed a significant
posttreatment decrease in COX-2 (P < 0.005; Table 4). Although a majority (12 of 20) of
participants showed posttreatment decreases in epithelial iNOS, these differences were not
statistically significant (P = 0.53; Table 4). Finally, the extent of gel application effects on
epithelial COX-2 and iNOS levels varied appreciably among patients (Table 4).
Superficial connective tissue MVD is diminished in some treated oral IEN lesions
Based on sample availability, MVD analyses were conducted on 11 pretreatment and
posttreatment matched tissues. Seven participants showed a decrease in MVD following gel
treatment (extent of decreases ranging from −2.9% to −67.3%; Table 4). Four of these positive
responders, which exhibited higher percentage MVD decreases [patient nos. 2 (−67.3%), 7
(−38.9%), 15 (−28.9%), and 20 (−19.8%)], also showed decreases in VEGF expression (−10,
−5.4, −1.1, and −1.8, for patient nos. 2, 7, 15 and 20, respectively; Tables 3 and 4; Fig. 2A and
B). Notably, the VEGF RT-PCR data from the three low positive responders (nos. 3, 10, and
14) and the four patients (nos. 13, 18, 19, and 21) which showed MVD increases (increases
ranging from +7.7% to +44.1%), also showed decreased VEGF expression in five patients,
three of which showed decreases of 2-fold or greater. These VEGF data likely reflect the
contribution of numerous factors in addition to transcriptional regulation that affects vascular
density.
Summarized data of black raspberry clinical trial reveals a cohort of “high” responders
The data presented in Table 4 depicts the overall effects of berry gel application on the 20
patients with oral IEN. The corresponding LOH indices data, which are discussed in a separate
report, are included for completeness (31). Three of the 20 patients (nos. 2, 9, and 12) showed
a high overall therapeutic responsiveness as determined by a >45% positive response rate.
Common features of the “high” responders were decreased iNOS protein (−27.7%, −24.1%,
and −16.0%), high responsiveness with respect to gene modulation (9, 6, and 8, respectively),
and no increases in histopathology (two decreased grade and one stable disease). The one high-
response participant (no. 2) who had sufficient tissues for MVD analyses also showed the
greatest posttreatment reduction (67.3%) in vascularity. The uniform features of the “low”
responders (≤30% positive response rate, nos. 5, 6, 8, 11, 15, 17, 18, and 21) were a
posttreatment increase in iNOS proteins in five of eight patients, either no change (nos. 6, 15,
18, 21) or an increase (nos. 8, 11, 17) in posttreatment histologic grade in seven of eight patients,
and modest to low gene-modulatory effects in eight of eight patients. Collectively, 60% of our
participants showed >30% positive therapeutic responses following treatment.
Follow-up information on clinical trial participants
Follow-up information regarding study participants (Table 1B) is limited by the complexion
of the patient pool in this regional referral center. Eleven patients remained as patients of record
at Ohio State and follow-up on these individuals ranged from 3 to 23 months. Three participants
(nos. 5, 9, and 15) have had no recurrences at the treated site with disease noted at other sites.
Three patients (nos. 3, 7, and 19) exhibited no change in disease status at the treatment site
with two of these three patients (nos. 3 and 19) developing lesions at other locations. Four
participants (nos. 1, 2, 10, and 14) showed disease progression at the treatment site, one patient
(no. 1) developed invasive SCC, and two patients (nos. 2 and 14) developed involvement of
other sites. The follow-up 7-month posttreatment biopsy of participant no. 21 showed a
histologic grade decrease at the treatment site.
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Our results show that application of a bioadhesive 10% FBR gel to oral IEN lesions showed
therapeutic efficacy without the induction of any adverse effects. These data further validate
the established safety record for the two cross-linked polyacrylic acid–based polymers used as
either the bioadhesive or the gel base (30) and are consistent with previous human studies
conducted by our laboratories, which used dietary berry administration (27–29).
Histopathology data show variability in oral IEN responsiveness, with 35% of our participants
demonstrating a lesional grade decrease, 20% of participants showing a lesional grade increase,
and 45% of the patients’ lesions exhibiting stable disease. Although modest, these histologic
response rates are comparable with previous oral IEN chemoprevention trials (36,37). A
previous study by Papadimitrakopoulou and colleagues, which evaluated the effects of 13-cis
retinoic acid, α-tocopherol, and IFN-α on oral and laryngeal IEN lesions, revealed that only
14% (one of seven) of the oral dysplastic lesions showed partial histologic regression at the
completion of the 12-month study, with 45% (5 of 11) demonstrating either partial or complete
regression at the intermediate 6th month assessment (36). As the rates of histologic regression
were higher in the laryngeal lesions, the investigators speculated that the more recalcitrant oral
cavity lesions had sustained different, potentially greater, molecular perturbations (36).
Similarly, another clinical trial which evaluated an ONXY-15–containing mouthwash that
targeted p53-defective epithelial cells reported a 37% histologic regression rate (37).
Microarray analyses revealed a consistent down-regulation in genes associated with RNA
processing, intracellular signaling, and antiapoptotic and proproliferative pathways. As
indicated by the number of genes affected, the greatest reduction occurred in RNA processing
genes, which could ultimately affect both transcription and translation (38). Notably, several
putative tumor-promoting genes showed posttreatment down-regulation including
heterogeneous ribonucleotide protein A1 (hnRNPA1). hnRNPA1 functions in diverse
biochemical interactions that include an overall regulation of transcription, augmentation of
telomerase activity, and increased IκBα degradation resulting in nuclear factor κB (NFκB)
activation (38). The other tumor-associated genes showed reduced expression function in
integrin-associated cell interactions (LGALS8), facilitation of chromosomal rearrangement
(RNASET2), and inhibition of apoptosis (CFLAR). These microarray data suggest that FBR
treatment diminishes overall transcriptional activity, resulting in less biochemically active
cells. Indeed, modulation towards more differentiated, less proliferative gene expression
profiles were observed in a subset of patients following gel application. As previous oral cavity
microarray studies have focused on obtaining “signature” gene expression profiles of normal,
premalignant and malignant oral tissues in the absence of treatment, direct comparisons with
our study are not feasible (34,35,39). In a recent esophageal chemoprevention trial, Joshi and
colleagues evaluated pretreatment and posttreatment gene expression profiles in histologically
normal esophageal tissues in 29 patients with premalignant esophageal lesions and identified
modified expression of 15 genes (40). Ten of these genes, which were associated with
inflammation and immune suppression, showed up-regulation during lesional progression,
whereas the expression of five genes associated with immune stimulation increased with
regression (40).
Our RT-PCR analyses revealed a large interpatient response range. Provided the outbred
human population, heterogeneity among premalignant lesions, and complexity of gene
regulation, these data were not surprising. Previous studies from our laboratories provide
mechanistic insights as to how FBR could modulate oral IEN gene expression and induce the
observed downstream effects (19–26). Huang and colleagues showed that a FBR methanol
extract reduced activator protein 1 (AP-1) activation by targeting mitogen-associated protein
kinase pathways including ERKs, JNKs, and p38K, and also suppressed NFκB activation by
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inhibiting IκBα phosphorylation (21). Notably, three potentially protumorigenic genes, i.e.,
COX-2, iNOS, and VEGF, all have NFκB-binding sites (40). Furthermore, AP-1 activation is
associated with up-regulation of COX-2 and VEGF (41). Our observed posttreatment decreases
in COX-2 and iNOS proteins, and the reduction of vascular densities, are therefore consistent
with FBR’s suppression of AP-1 and NFκB activation. The methanol FBR extract also inhibited
the activation of a key cell survival and proangiogenic signaling pathway, i.e.,
phosphoinositide-3-kinase/Akt (19). Additional studies, which showed that an ethanol FBR
extract reduced VEGF production and increased the functional activities of caspase 3 and
keratinocyte-specific transglutaminase in human oral SCC cells, showed FBR’s downstream
effects on apoptotic, differentiation, and angiogenic proteins (22).
The majority of IEN patients showed decreases in epithelial COX-2 and iNOS proteins
following treatment. These data are consistent with our previous results which showed that
dietary FBR administration reduced COX-2 and iNOS proteins in a rat esophageal cancer
model (26). Questions arise, however, regarding what extent of decreases are
pathophysiologically significant. Perhaps equally or potentially more important, are the COX-2
and iNOS enzyme levels relative to the reactive species degrading enzymes within critical cell
populations. High COX-2 and iNOS activities in rapidly dividing cells, such as the transient
amplifying cell population, or in the stem cell pool, have the potential to induce consequential,
tumor-promoting nuclear and mitochondrial mutations (7,12). Furthermore, high production
of prostanoids and reactive nitrogen species by cells in communication with the underlying
connective tissue facilitates angiogenesis (7,12). Our MVD results did not reveal any clear
associations between the treatment effects on VEGF expression and the corresponding MVD.
These data likely reflect the varied factors associated with angiogenesis, including multiple
VEGF splice variants which may have varying biological efficacies, translational and
posttranslational modifications of proangiogenic proteins, local levels of proangiogenic
factors, and the requirement for activated endothelial cells (42).
The extent of therapeutic efficacy necessary to be deemed a positive outcome in human clinical
trials remains to be defined. A recent oral IEN clinical trial stipulated a priori that their tested
agent would be considered active if 14.3% of their patients showed a positive response (43).
Our clinical trial results identify a subset of high therapeutic responders, and also indicated
that 60% of our patients showed a >30% positive response rate. Several factors such as
sustainability and penetration of compounds at the treatment site and compound stabilization
or metabolic bioactivation at the target tissues all likely affect clinical outcomes. It is also
feasible that an optimized dose or dosing schedule may improve our therapeutic responses.
Our follow-up data, which implies that longer duration treatment will likely be necessary for
patients with oral IEN, emphasizes the need to identify both effective and well-tolerated agents.
Previous oral IEN clinical trials have relied primarily on systemic agent administration,
resulting in some toxicities and concerns regarding sufficient agent availability at the treatment
site (36,43–45). Although local delivery via a mouthwash was recently used in an oral IEN
trial, this study was discontinued after a patient developed circulating antibodies to the
adenovirus vector (37). Aspects of this current study, i.e., the local delivery of naturally derived
chemopreventives, have modified the oral IEN chemoprevention paradigm. Finally, although
this trial should be considered exploratory due to its modest size and relatively short duration,
therapeutically promising data have been obtained.
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Although the majority of patients with oral IEN showed a reduction in epithelial levels of
COX-2 and iNOS at the conclusion of the trial, the extent of protein decreases varied among
patients. The pretreatment COX-2 photomicrograph of patient no. 20 shows moderate to
intense positivity in the spinous and granular layers, which was markedly reduced following
treatment (88.9% decrease for patient no. 20). In contrast, iNOS showed a more uniform
distribution throughout the epithelium, inclusive of basal cell staining, as is apparent in the
pretreatment iNOS photomicrograph for patient no. 9. This patient showed an overall high
therapeutic response rate (47.4%), inclusive of a 24.1% decrease in epithelial iNOS following
berry gel application (all photomicrographs taken at × 100 image scale, using an Olympus
BX51 microscope equipped with a Nikon DS-Fi1 digital camera).
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Eleven clinical trial participants retained sufficient pretreatment and posttreatment tissues for
the evaluation of the effects of berry gel on MVD. A, seven of the 11 participants showed
posttreatment decreases, with four participants showing MVD reductions that ranged from
19.8% to 67.3%. B, pretreatment and posttreatment photomicrographs of patient no. 2. This
individual showed the highest overall therapeutic response rate of 60%, including a decrease
in lesional histologic grade apparent in the H&E-stained sections (pretreatment diagnosis—
mild dysplasia; posttreatment diagnosis—atypia) and a 67.3% reduction in MVD, as noted in
the pretreatment and posttreatment CD34 sections (all photomicrographs taken at ×100 image
scale using an Olympus BX51 microscope equipped with a Nikon DS-Fi1 digital camera).
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